Table 5.

Comparison of noninvasive biomarkers pre- and post-treatment in the subjects with either noninvasive biomarker-detected advanced hepatic fibrosis (nAHF) or no evidence of noninvasive biomarker-detected advanced hepatic fibrosis (no nAHF) using Model 2.

	APRI	Fib4	TE	Hepascore	Ferritin (µg/L)
nAHF
Pre-treatment	0.77 ± 0.12	1.6 ± 0.3	6.0 ± 1.1	0.17 ± 0.06	1188 ± 250
Post-treatment	0.57 ± 0.20	1.4 ± 0.3	4.4 ± 0.7	0.29 ± 0.18	328 ± 53*
No nAHF
Pre-treatment	0.25 ± 0.01	0.68 ± 0.03	4.8 ± 0.2	0.20 ± 0.01	484 ± 19
Post-treatment	0.30 ± 0.04	0.88 ± 0.16	4.9 ± 0.2	0.19 ± 0.01	321 ± 22***

Results are shown as mean ± SE.

APRI: aspartate aminotransferase to platelet ratio index; Fib4: fibrosis-4; nAHF: noninvasive biomarker advanced hepatic fibrosis; No nAHF: no noninvasive biomarker advanced hepatic fibrosis; TE: transient elastography.

*P < 0.05, ***P < 0.0001 compared with pre-treatment (paired t test).